Hepatic insulin clearance is the primary determinant of insulin sensitivity in the normal dog
- PMID: 24123967
- PMCID: PMC3969862
- DOI: 10.1002/oby.20625
Hepatic insulin clearance is the primary determinant of insulin sensitivity in the normal dog
Abstract
Objective: Insulin resistance is a powerful risk factor for Type 2 diabetes and a constellation of chronic diseases, and is most commonly associated with obesity. We examined if factors other than obesity are more substantial predictors of insulin sensitivity under baseline, nonstimulated conditions.
Methods: Metabolic assessment was performed in healthy dogs (n = 90). Whole-body sensitivity from euglycemic clamps (SICLAMP ) was the primary outcome variable, and was measured independently by IVGTT (n = 36). Adiposity was measured by MRI (n = 90), and glucose-stimulated insulin response was measured from hyperglycemic clamp or IVGTT (n = 86 and 36, respectively).
Results: SICLAMP was highly variable (5.9-75.9 dl/min per kg per μU/ml). Despite narrow range of body weight (mean, 28.7 ± 0.3 kg), adiposity varied approximately eight-fold and was inversely correlated with SICLAMP (P < 0.025). SICLAMP was negatively associated with fasting insulin, but most strongly associated with insulin clearance. Clearance was the dominant factor associated with sensitivity (r = 0.53, P < 0.00001), whether calculated from clamp or IVGTT.
Conclusions: These data suggest that insulin clearance contributes substantially to insulin sensitivity, and may be pivotal in understanding the pathogenesis of insulin resistance. We propose the hyperinsulinemia due to reduction in insulin clearance is responsible for insulin resistance secondary to changes in body weight.
Copyright © 2013 The Obesity Society.
Figures
References
-
- Hollenbeck C, Reaven GM. Variations in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance. J Clin Endocrinol Metab. 1987;64:1169–1173. - PubMed
-
- Mittelman SD, van Citters GW, Kim SP, Davis DA, Dea MK, Bergman RN. The longitudinal compensation for fat induced insulin resistance includes reduced insulin clearance and enhanced B-cell response. Diabetes. 2000;49:2116–2125. - PubMed
-
- Erdmann J, Kallabis B, Oppel U, Sypchenko O, Wagenpfeil S, Schusdziarra V. Development of hyperinsulinemia and insulin resistance during the early stage of weight gain. Am J Physiol. 2008;294:E568–E575. - PubMed
-
- Ader M, Kim SP, Catalano KC, Ionut V, Hucking K, Richey JM, et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: placebo-controlled study of olanzapine and risperidone in dogs. Diabetes. 2005;54:862–871. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
